Roche to Buy Telavant From Roivant Sciences and Pfizer in $7.25 Bln Deal

Singapore News News

Roche to Buy Telavant From Roivant Sciences and Pfizer in $7.25 Bln Deal
Singapore Latest News,Singapore Headlines
  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 48 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 22%
  • Publisher: 97%

By Adria Calatayud Roche Holding has agreed to buy Telavant Holdings from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion that will give it...

Roche Holding has agreed to buy Telavant Holdings from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion that will give it rights to a therapy for inflammatory bowel disease and potentially multiple other indications.

The Swiss pharmaceutical giant said Monday that it will pay $7.1 billion upfront and make a near-term milestone payment of $150 million to acquire rights to develop and manufacture Telavant's RVT-3101 drug candidate and commercialize it in the U.S. and in Japan. Telavant was jointly formed by Roivant and Pfizer last year to develop and commercialize RVT-3101 in the U.S. and Japan, with Roivant owning a 75% stake and Pfizer holding the remaining 25%, Roche said.

RVT-3101 is an antibody drug in development for people suffering from inflammatory bowel disease--a chronic gastrointestinal disorder--that has potential to be applied in multiple other diseases given that it targets both inflammation and fibrosis, Roche said. As part of the agreement, Roche will also have an option to enter into a global collaboration with Pfizer for a next-generation antibody called p40/TL1A that is currently in early-stage clinical trials.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

MarketWatch /  🏆 3. in US

Singapore Latest News, Singapore Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

India is a ‘slow trundling elephant' but a viable alternative to China, says veteran investor David RocheIndia is a ‘slow trundling elephant' but a viable alternative to China, says veteran investor David RocheVeteran Investor David Roche said India has been aligning itself with the “democratic alliances” of the “richest and most vibrant…
Read more »

India is a ‘slow trundling elephant’ but a viable alternative to China, says veteran investor David RocheIndia is a ‘slow trundling elephant’ but a viable alternative to China, says veteran investor David RocheVeteran Investor David Roche said India has been aligning itself with the 'democratic alliances' of the 'richest and most vibrant economies' in the world.
Read more »

Solar Panels and Nuclear EnergySolar Panels and Nuclear EnergySaleem H. Ali is Chair of the Department of Geography and Spatial Sciences and the Blue & Gold Distinguished Professor of Energy and the Environment at the University of Delaware (USA).
Read more »

Philadelphia Orchestra and musicians agree to 3-year labor deal with 15.8% salary increasePhiladelphia Orchestra and musicians agree to 3-year labor deal with 15.8% salary increaseMusicians of the Philadelphia Orchestra and the Philadelphia Orchestra Association have ratified a collective bargaining agreement calling for minimum salaries to increase by 15.8% over three years. The deal with Local 77 of the American Federation of Musicians covers Sept. 11 this year through Sept. 13, 2026.
Read more »

5 Shopping Editors Agree: These Comfy Everlane Finds Deserve a Spot in Your Fall Closet5 Shopping Editors Agree: These Comfy Everlane Finds Deserve a Spot in Your Fall ClosetInStyle shopping editors and writers share their fall fashion picks available at Everlane. Shop oversized blazers, leather Chelsea boots, trench coats, and more comfy finds from the brand.
Read more »



Render Time: 2025-02-28 06:03:25